Serendipity in the search for “morning-after pills” led to clomiphene for the induction of ovulation
F&S Science · 2020
DOI: 10.1016/j.xfss.2020.07.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift F&S Science, 2020. Verfasst von V Craig Jordan. Beteiligte Einrichtung: Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas. Electronic address: VCJordan@mdanderson.org. Die Arbeit nennt 85 Literaturangaben. Gefördert von: American Cancer Society.
Abstract (Originalsprache)
The approval of the oral contraceptive on June 23, 1960, by the United States Food and Drug Administration (FDA), changed society forever. For the first time, a pill designed and tested by men, supported by influential women, allowed women to control their fertility. For the first time, the FDA approved a medicine to be taken by humans without a disease. The chance discovery of a new group of medicines called nonsteroidal antiestrogens, created an opportunity for the pharmaceutical industry. These compounds were shown to be postcoital antifertility agents in rats and mice. In the 1960s, the development of a "morning-after pill" would have had an enormous market. Numerous companies focused discovery efforts to evaluate the development of their patented nonsteroidal antiestrogens: Merrell (clomiphene), Upjohn (U-11,100A), and ICI Pharmaceutical Division (ICI46,474). However, the antifertility effects of antiestrogens in rats and mice does not mean that the new medicine would be an antifertility agent in women. In this case, clomiphene did exactly the opposite of what it was predicted to prevent. Clomiphene became the first medicine to induce ovulation in subfertile women. This article describes the twists and turns of drug discovery and development over the past half century. The conclusion emphasizes the evolution of drug development over decades, based on fashions in medical research and discoveries in clinical pharmacology. As a result, new uses for old molecules, that started life as "nonsteroidal antiestrogens," have revolutionized women's health as members of the new group of medicines called selective estrogen receptor modulators.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas. Electronic address: VCJordan@mdanderson.org.
Förderung
- American Cancer Society
Zitieren
APA
Jordan, V. C. (2020). Serendipity in the search for “morning-after pills” led to clomiphene for the induction of ovulation. F&S Science. https://doi.org/10.1016/j.xfss.2020.07.002
Vancouver
Jordan VC. Serendipity in the search for “morning-after pills” led to clomiphene for the induction of ovulation. F&S Science. 2020. doi:10.1016/j.xfss.2020.07.002
BibTeX
@article{Jordan2020,
author = {Jordan, V Craig},
title = {Serendipity in the search for “morning-after pills” led to clomiphene for the induction of ovulation},
journal = {F&S Science},
year = {2020},
doi = {10.1016/j.xfss.2020.07.002}
}
EUVIMED